Article (Scientific journals)
Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria
Wybo, Ingrid; Piérard, Denis; Verschraegen, Inge et al.
2007In Journal of Antimicrobial Chemotherapy, 59 (1), p. 132-139
Peer Reviewed verified by ORBi
 

Files


Full Text
J. Antimicrob. Chemother.-2007-Wybo-132-9.pdf
Publisher postprint (118.59 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
anaerobes; Etest; surveillance; empirical therapy
Abstract :
[en] Objectives: To collect recent data on the susceptibility of anaerobes and to compare them with results from previous studies. Methods: Four hundred and forty-three anaerobic clinical isolates from various body sites were prospectively collected from October 2003 to February 2005 in nine Belgian hospitals. MICs were determined for nine anti-anaerobic and three recently developed antibiotics. Results: Most Gram-negative bacilli except Fusobacterium spp. were resistant to penicillin. Piperacillin/tazobactam, metronidazole, chloramphenicol, meropenem and amoxicillin/clavulanic acid were very active against all groups, but only 86% of Bacteroides fragilis group strains were susceptible to the latter. Cefoxitin, cefotetan and clindamycin were less active. In particular, only 62%, 52% and 48% of B. fragilis group strains were susceptible, respectively. Clindamycin shows a continuing decrease in activity, as 83% were still susceptible in 1987 and 66% in 1993-94. Anti-anaerobic activity of the new antibiotics is interesting, with MIC50 and MIC90 of 1 and > 32 mg/L for moxifloxacin, 2 and 4 mg/L for linezolid and 0.5 and 8 mg/L for tigecycline. Conclusions: The susceptibility of anaerobic bacteria remains stable in Belgium, except for clindamycin, which shows a continuous decrease in activity. However, for each of the tested antibiotics, at least a few resistant organisms were detected. Consequently, for severe infections involving anaerobic bacteria, it could be advisable to perform microbiological testing instead of relying on known susceptibility profiles. Periodically monitoring background susceptibility remains necessary to guide empirical therapy.
Disciplines :
Immunology & infectious disease
Microbiology
Pharmacy, pharmacology & toxicology
Author, co-author :
Wybo, Ingrid;  Academisch Ziekenhuis Vrije Universiteit Brussel > Clinical Microbiology
Piérard, Denis ;  Academisch Ziekenhuis Vrije Universiteit Brussel > Clinical Bacteriology
Verschraegen, Inge;  Academisch Ziekenhuis Vrije Universiteit Brussel,
Reynders, Marijke;  Universitair Medisch Centrum Sint-Pieter, Brussels
Vandoorslaer, Kristof;  Academisch Ziekenhuis Vrije Universiteit Brussel
Claeys, Geert;  Universitair Ziekenhuis Gent - UZ
Delmee, Michel;  Cliniques Universitaires Saint-Luc, Brussels
Glupczynski, Youri;  Cliniques Universitaires de Mont-Godinne, Yvoir
Gordts, Bart;  Algemeen Ziekenhuis Sint-Jan, Bruges
Ieven, Margaretha;  Universitair Ziekenhuis Antwerpen - UZA
Melin, Pierrette  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Microbiologie médicale et virologie médicale
Struelens, Marc;  Hôpital Universitaire Erasme - ULB > Microbiologie
Verhaegen, Jan;  Universitair Ziekenhuis Leuven -KUL
Lauwers, Sabine;  Academisch Ziekenhuis Vrije Universiteit Brussel
More authors (4 more) Less
Language :
English
Title :
Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria
Publication date :
January 2007
Journal title :
Journal of Antimicrobial Chemotherapy
ISSN :
0305-7453
eISSN :
1460-2091
Publisher :
Oxford Univ Press, Oxford, United Kingdom
Volume :
59
Issue :
1
Pages :
132-139
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 11 December 2010

Statistics


Number of views
103 (6 by ULiège)
Number of downloads
224 (2 by ULiège)

Scopus citations®
 
77
Scopus citations®
without self-citations
70
OpenCitations
 
57

Bibliography


Similar publications



Contact ORBi